Heather L Kimmel

List of Publications by Year
in descending order

96	3,872	147801 31	138484 58
papers	citations	h-index	g-index

98	98	98	3449
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Variability in Urinary Nicotine Exposure Biomarker Levels Between Waves 1 (2013â€“2014) and 2 (2014â€“2015) in the Population Assessment of Tobacco and Health Study. Nicotine and Tobacco Research, 2023, 25, 616-623.	2.6	2
2	Predictors of E-cigarette and Cigarette Use Trajectory Classes from Early Adolescence to Emerging Adulthood Across Four Years (2013â€“2017) of the PATH Study. Nicotine and Tobacco Research, 2023, 25, 421-429.	2.6	5
3	Validation of the Wave 1 and Wave 2 Population Assessment of Tobacco and Health (PATH) Study Indicators of Tobacco Dependence Using Biomarkers of Nicotine Exposure Across Tobacco Products. Nicotine and Tobacco Research, 2022, 24, 10-19.	2.6	13
4	Urinary Nicotine Metabolites and Self-Reported Tobacco Use Among Adults in the Population Assessment of Tobacco and Health (PATH) Study, 2013â€“2014. Nicotine and Tobacco Research, 2022, 24, 768-777.	2.6	10
5	Serum Concentrations of Cotinine and Trans-3â€²-Hydroxycotinine in US Adults: Results From Wave 1 (2013â€“2014) of the Population Assessment of Tobacco and Health Study. Nicotine and Tobacco Research, 2022, 24, 736-744.	2.6	6
6	Changes in Biomarkers of Tobacco Exposure among Cigarette Smokers Transitioning to ENDS Use: The Population Assessment of Tobacco and Health Study, 2013â€“2015. International Journal of Environmental Research and Public Health, 2022, 19, 1462.	2.6	15
7	Cardiovascular Outcomes among Combustible-Tobacco and Electronic Nicotine Delivery System (ENDS) Users in Waves 1 through 5 of the Population Assessment of Tobacco and Health (PATH) Study, 2013â€“2019. International Journal of Environmental Research and Public Health, 2022, 19, 4137.	2.6	4
8	Tobacco Product Use and Functionally Important Respiratory Symptoms Among US Adolescents/Young Adults. Academic Pediatrics, 2022, 22, 1006-1016.	2.0	8
9	Tobacco Use and Respiratory Symptoms Among Adults: Findings From the Longitudinal Population Assessment of Tobacco and Health (PATH) Study 2014â€“2016. Nicotine and Tobacco Research, 2022, 24, 1607-1618.	2.6	13
10	Factors associated with changes in flavored tobacco products used: Findings from wave 2 and wave 3 (2014â€“2016) of the population assessment of tobacco and health (PATH) study. Addictive Behaviors, 2022, 130, 107290.	3.0	5
11	Oral Health in the Population Assessment of Tobacco and Health Study. Journal of Dental Research, 2022, 101, 1046-1054.	5.2	8
12	Correlates of tobacco product initiation among youth and young adults between waves 1â€“4 of the population assessment of tobacco and Health (PATH) study (2013â€“2018). Addictive Behaviors, 2022, 134, 107396.	3.0	3
13	Tobacco-Specific Nitrosamines (NNAL, NNN, NAT, and NAB) Exposures in the US Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013â€“2014). Nicotine and Tobacco Research, 2021, 23, 573-583.	2.6	30
14	Adultsâ€™ E-Cigarette Flavor Use and Cigarette Quit Attempts: Population Assessment of Tobacco and Health Study Findings. American Journal of Preventive Medicine, 2021, 60, 300-302.	3.0	7
15	Exposure to Nicotine and Toxicants Among Dual Users of Tobacco Cigarettes and E-Cigarettes: Population Assessment of Tobacco and Health (PATH) Study, 2013â€“2014. Nicotine and Tobacco Research, 2021, 23, 790-797.	2.6	15
16	Urinary Cotinine and Cotinine + Trans-3â€²-Hydroxycotinine (TNE-2) Cut-points for Distinguishing Tobacco Use from Nonuse in the United States: PATH Study (2013â€“2014). Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1175-1184.	2.5	13
17	Smoking Susceptibility and Tobacco Media Engagement Among Youth Never Smokers. Pediatrics, 2021, 147, .	2.1	13
18	Cardiovascular Risk Factor and Disease Measures from the Population Assessment of Tobacco and Health (PATH) Study. International Journal of Environmental Research and Public Health, 2021, 18, 7692.	2.6	9

#	Article	IF	Citations
19	Biomarkers of Inflammation and Oxidative Stress among Adult Former Smoker, Current E-Cigarette Usersâ€"Results from Wave 1 PATH Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1947-1955.	2.5	14
20	Validation of an Index for Functionally Important Respiratory Symptoms among Adults in the Nationally Representative Population Assessment of Tobacco and Health Study, 2014â€"2016. International Journal of Environmental Research and Public Health, 2021, 18, 9688.	2.6	6
21	Qualitative insights on how adult e-cigarette users describe quantity of e-cigarettes used â€" PATH Study 2018. Preventive Medicine Reports, 2021, 23, 101421.	1.8	4
22	Association of e-Cigarette Use With Discontinuation of Cigarette Smoking Among Adult Smokers Who Were Initially Never Planning to Quit. JAMA Network Open, 2021, 4, e2140880.	5.9	29
23	Predictive validity of the adult tobacco dependence index: Findings from waves 1 and 2 of the Population Assessment of Tobacco and Health (PATH) study. Drug and Alcohol Dependence, 2020, 214, 108134.	3.2	25
24	Urinary Biomarkers of Exposure to Volatile Organic Compounds from the Population Assessment of Tobacco and Health Study Wave 1 (2013â€"2014). International Journal of Environmental Research and Public Health, 2020, 17, 5408.	2.6	29
25	Overview of tobacco use transitions for population health. Tobacco Control, 2020, 29, s134-s138.	3.2	13
26	Initiation of any tobacco and five tobacco products across 3 years among youth, young adults and adults in the USA: findings from the PATH Study Waves 1â€"3 (2013â€"2016). Tobacco Control, 2020, 29, s178-s190.	3.2	45
27	Longitudinal transitions of exclusive and polytobacco electronic nicotine delivery systems (ENDS) use among youth, young adults and adults in the USA: findings from the PATH Study Waves 1â€"3 (2013â€"2016). Tobacco Control, 2020, 29, s147-s154.	3.2	52
28	Longitudinal pathways of exclusive and polytobacco hookah use among youth, young adults and adults in the USA: findings from the PATH Study Waves 1â€"3 (2013â€"2016). Tobacco Control, 2020, 29, s155-s162.	3.2	31
29	Longitudinal pathways of exclusive and polytobacco smokeless use among youth, young adults and adults in the USA: findings from the PATH Study Waves 1â€"3 (2013â€"2016). Tobacco Control, 2020, 29, s170-s177.	3.2	42
30	Longitudinal pathways of exclusive and polytobacco cigarette use among youth, young adults and adults in the USA: findings from the PATH Study Waves 1â€"3 (2013â€"2016). Tobacco Control, 2020, 29, s139-s146.	3.2	38
31	Correlates of tobacco product reuptake and relapse among youth and adults in the USA: findings from the PATH Study Waves 1â€"3 (2013â€"2016). Tobacco Control, 2020, 29, s216-s226.	3.2	28
32	Correlates of tobacco product initiation among youth and adults in the USA: findings from the PATH Study Waves 1â€"3 (2013â€"2016). Tobacco Control, 2020, 29, s191-s202.	3.2	49
33	Correlates of tobacco product cessation among youth and adults in the USA: findings from the PATH Study Waves 1â€"3 (2013â€"2016). Tobacco Control, 2020, 29, s203-s215.	3.2	46
34	Longitudinal pathways of exclusive and polytobacco cigar use among youth, young adults and adults in the USA: findings from the PATH Study Waves 1â€"3 (2013â€"2016). Tobacco Control, 2020, 29, s163-s169.	3.2	36
35	Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16. PLoS ONE, 2020, 15, e0237938.	2.5	48
36	Biomarkers of Exposure among USA Adult Hookah Users: Results from Wave 1 of the Population Assessment of Tobacco and Health (PATH) Study (2013â€"2014). International Journal of Environmental Research and Public Health, 2020, 17, 6403.	2.6	7

#	Article	IF	Citations
37	Association of Electronic Nicotine Delivery System Use With Cigarette Smoking Relapse Among Former Smokers in the United States. JAMA Network Open, 2020, 3, e204813.	5.9	34
38	Biomarkers of Exposure among Adult Smokeless Tobacco Users in the Population Assessment of Tobacco and Health Study (Wave 1, 2013â€“2014). Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 659-667.	2.5	18
39	Longitudinal associations between susceptibility to tobacco use and the onset of other substances among U.S. youth. Preventive Medicine, 2020, 135, 106074.	3.4	10
40	Nicotine Exposure by Device Type among Adult Electronic Nicotine Delivery System Users in the Population Assessment of Tobacco and Health Study, 2015â€“2016. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1968-1972.	2.5	5
41	Association of Electronic Nicotine Delivery System Use With Cigarette Smoking Progression or Reduction Among Young Adults. JAMA Network Open, 2020, 3, e2015893.	5.9	5
42	Longitudinal e-Cigarette and Cigarette Use Among US Youth in the PATH Study (2013â€“2015). Journal of the National Cancer Institute, 2019, 111, 1088-1096.	6.3	40
43	Urinary concentrations of monohydroxylated polycyclic aromatic hydrocarbons in adults from the U.S. Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013â€“2014). Environment International, 2019, 123, 201-208.	10.0	38
44	Biomarkers of Exposure Among U.S. Adult Cigar Smokers: Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013-2014). Cancer Epidemiology Biomarkers and Prevention, 2019, 28, cebp.0539.2018.	2.5	30
45	Associations of risk factors of e-cigarette and cigarette use and susceptibility to use among baseline PATH study youth participants (2013â€“2014). Addictive Behaviors, 2019, 91, 51-60.	3.0	37
46	Patterns and correlates of polysubstance use among US youth aged 15â€“17Âyears: wave 1 of the Population Assessment of Tobacco and Health (PATH) Study. Addiction, 2019, 114, 907-916.	3.3	35
47	Body mass index and tobacco-product use among U.S. youth: Findings from wave 1 (2013â€“2014) of the Population Assessment of Tobacco and Health (PATH) Study. Addictive Behaviors, 2018, 81, 91-95.	3.0	8
48	Transitions in electronic cigarette use among adults in the Population Assessment of Tobacco and Health (PATH) Study, Waves 1 and 2 (2013â€“2015). Tobacco Control, 2018, 28, tobaccocontrol-2017-054174.	3.2	105
49	US Adult Cigar Smoking Patterns, Purchasing Behaviors, and Reasons for Use According to Cigar Type: Findings From the Population Assessment of Tobacco and Health (PATH) Study, 2013â€“2014. Nicotine and Tobacco Research, 2018, 20, 1457-1466.	2.6	88
50	Co-occurrence of tobacco product use, substance use, and mental health problems among youth: Findings from wave 1 (2013â€“2014) of the population assessment of tobacco and health (PATH) study. Addictive Behaviors, 2018, 76, 208-217.	3.0	85
51	Comparison of Nicotine and Toxicant Exposure in Users of Electronic Cigarettes and Combustible Cigarettes. JAMA Network Open, 2018, 1, e185937.	5.9	361
52	Cannabis Use Disorder: Recent Findings and Future Directions. Current Addiction Reports, 2018, 5, 397-402.	3.4	8
53	Design and methods of the Population Assessment of Tobacco and Health (PATH) Study. Tobacco Control, 2017, 26, 371-378.	3.2	642
54	Electronic cigarette use among US adults in the Population Assessment of Tobacco and Health (PATH) Study, 2013â€“2014. Tobacco Control, 2017, 26, e117-e126.	3.2	161

#	Article	IF	Citations
55	Biomarkers of exposure to new and emerging tobacco delivery products. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L425-L452.	2.9	95
56	Co-occurrence of tobacco product use, substance use, and mental health problems among adults: Findings from Wave 1 (2013â€“2014) of the Population Assessment of Tobacco and Health (PATH) Study. Drug and Alcohol Dependence, 2017, 177, 104-111.	3.2	141
57	Effects of Pharmacologic Dopamine Î²-Hydroxylase Inhibition on Cocaine-Induced Reinstatement and Dopamine Neurochemistry in Squirrel Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 144-152.	2.5	18
58	Chronic Interferon-Î± Decreases Dopamine 2 Receptor Binding and Striatal Dopamine Release in Association with Anhedonia-Like Behavior in Nonhuman Primates. Neuropsychopharmacology, 2013, 38, 2179-2187.	5.4	158
59	Neurobiological Changes Mediating the Effects of Chronic Fluoxetine on Cocaine Use. Neuropsychopharmacology, 2012, 37, 1816-1824.	5.4	29
60	The Serotonin 2C Receptor Antagonist SB 242084 Exhibits Abuse-Related Effects Typical of Stimulants in Squirrel Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2012, 342, 761-769.	2.5	31
61	Effects of Serotonin 2C Receptor Agonists on the Behavioral and Neurochemical Effects of Cocaine in Squirrel Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 424-434.	2.5	63
62	Add Ecology to the Pre-Medical Curriculum. Science, 2012, 335, 1301-1301.	12.6	7
63	The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine (â€œecstasyâ€): A concurrent microdialysis and plasma analysis study. Hormones and Behavior, 2012, 61, 181-190.	2.1	22
64	Simultaneous measurement of extracellular dopamine and dopamine transporter occupancy by cocaine analogs in squirrel monkeys. Synapse, 2012, 66, 501-508.	1.2	11
65	The cystineâ€“glutamate transporter enhancer N-acetyl-l-cysteine attenuates cocaine-induced changes in striatal dopamine but not self-administration in squirrel monkeys. Pharmacology Biochemistry and Behavior, 2012, 101, 288-296.	2.9	21
66	Effects of dopamine betaâ€hydroxylase (DBH) inhibition on cocaineâ€induced reinstatement in squirrel monkeys. FASEB Journal, 2012, 26, 659.9.	0.5	0
67	Acute administration of cocaine decreases cell surface expression of DAT in the squirrel monkey caudate. FASEB Journal, 2011, 25, 1083.3.	0.5	0
68	Effects of the monoamine uptake inhibitors RTI-112 and RTI-113 on cocaine- and food-maintained responding in rhesus monkeys. Pharmacology Biochemistry and Behavior, 2009, 91, 333-338.	2.9	12
69	Interactions between the mGluR2/3 agonist, LY379268, and cocaine on in vivo neurochemistry and behavior in squirrel monkeys. Pharmacology Biochemistry and Behavior, 2009, 94, 204-210.	2.9	29
70	Behavioral and neurochemical effects of amphetamine analogs that release monoamines in the squirrel monkey. Pharmacology Biochemistry and Behavior, 2009, 94, 278-284.	2.9	18
71	Monoamine transporters and psychostimulant addiction. Biochemical Pharmacology, 2008, 75, 196-217.	4.4	189
72	Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys. Pharmacology Biochemistry and Behavior, 2008, 90, 453-462.	2.9	42

#	Article	IF	Citations
73	Effects of Combined Dopamine and Serotonin Transporter Inhibitors on Cocaine Self-Administration in Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 757-765.	2.5	69
74	Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys. Pharmacology Biochemistry and Behavior, 2007, 86, 45-54.	2.9	51
75	Intra-VTA CART 55-102 reduces the locomotor effect of systemic cocaine in rats: An isobolographic analysis. Neuropeptides, 2007, 41, 65-72.	2.2	32
76	Role of mGluR2/3 in the behavioralâ€stimulant effects of cocaine in squirrel monkeys. FASEB Journal, 2007, 21, A777.	0.5	0
77	Olanzapine-Induced Suppression of Cocaine Self-Administration in Rhesus Monkeys. Neuropsychopharmacology, 2006, 31, 585-593.	5.4	12
78	Effects of Nâ€acetylcysteine on the behavioralâ€stimulant, reinforcing, and neurochemical effects of cocaine in the squirrel monkey. FASEB Journal, 2006, 20, A675.	0.5	0
79	Interaction of cocaine and dopamine transporter inhibitors on behavior and neurochemistry in monkeys. Pharmacology Biochemistry and Behavior, 2005, 80, 481-491.	2.9	18
80	Changes in extracellular dopamine during cocaine self-administration in squirrel monkeys. Synapse, 2005, 56, 129-134.	1.2	25
81	In vivo comparison of the reinforcing and dopamine transporter effects of local anesthetics in rhesus monkeys. Synapse, 2005, 58, 220-228.	1.2	33
82	CART peptides are modulators of mesolimbic dopamine and psychostimulants. Life Sciences, 2003, 73, 741-747.	4.3	77
83	Withdrawal from Repeated Cocaine Alters Dopamine Transporter Protein Turnover in the Rat Striatum. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 15-21.	2.5	25
84	Activity of various CART peptides in changing locomotor activity in the rat. Neuropeptides, 2002, 36, 9-12.	2.2	39
85	Locomotor stimulant effects of novel phenyltropanes in the mouse. Drug and Alcohol Dependence, 2001, 65, 25-36.	3.2	19
86	Neurotransmitter transporters. Life Sciences, 2001, 68, 2181-2185.	4.3	9
87	Repeated cocaine administration does not alter morphine-induced rotational behavior in nigrally denervated rats. Behavioural Pharmacology, 2001, 12, 101-108.	1.7	6
88	RTI-76, an irreversible inhibitor of dopamine transporter binding, increases locomotor activity in the rat at high doses. Brain Research, 2001, 897, 157-163.	2.2	6
89	Dopamine transporter synthesis and degradation rate in rat striatum and nucleus accumbens using RTI-76. Neuropharmacology, 2000, 39, 578-585.	4.1	37
90	Sensitization to Daily Morphine Injections in Rats With Unilateral Lesions of the Substantia Nigra. Pharmacology Biochemistry and Behavior, 1999, 64, 487-493.	2.9	12

#	Article	IF	Citations
91	Naloxone does not alter amphetamine-induced rotational behavior or striatal dopamine levels of nigrally-lesioned rats. Brain Research, 1998, 789, 171-174.	2.2	1
92	Opioid receptor agonists and antagonists alter GBR12909-induced turning in the rat. European Journal of Pharmacology, 1998, 343, 119-127.	3.5	4
93	Dissociation of morphine-induced potentiation of turning and striatal dopamine release by amphetamine in the nigrally-lesioned rat. European Journal of Pharmacology, 1998, 346, 203-208.	3.5	12
94	Synergism between buprenorphine and cocaine on the rotational behavior of the nigrally-lesioned rat. Psychopharmacology, 1997, 133, 372-377.	3.1	25
95	Theory and statistics of detecting synergism between two active drugs: cocaine and buprenorphine. Psychopharmacology, 1997, 133, 378-382.	3.1	35
96	Effects of acute and chronic morphine on rotational behavior in nigral-lesioned rats. Pharmacology Biochemistry and Behavior, 1995, 52, 397-401.	2.9	8